NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$33.40
+0.30 (+0.91 %)
(As of 08/2/2021 10:28 AM ET)
Add
Compare
Today's Range
$33.32
$33.64
50-Day Range
$30.73
$37.64
52-Week Range
$24.77
$55.22
Volume267 shs
Average Volume278,990 shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2
30 days | 90 days | 365 days | Advanced Chart
Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Y-mAbs Therapeutics logo

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.52 out of 5 stars

Medical Sector

100th out of 2,221 stocks

Pharmaceutical Preparations Industry

52nd out of 869 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

Is Y-mAbs Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Y-mAbs Therapeutics
.

How can I listen to Y-mAbs Therapeutics' earnings call?

Y-mAbs Therapeutics will be holding an earnings conference call on Friday, August 6th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) issued its earnings results on Thursday, May, 6th. The company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.61 by $0.14. The firm had revenue of $5.38 million for the quarter, compared to analyst estimates of $35.67 million.
View Y-mAbs Therapeutics' earnings history
.

How has Y-mAbs Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, YMAB shares have increased by 45.3% and is now trading at $33.40.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for YMAB?

7 equities research analysts have issued 1 year price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $45.00 to $68.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $55.14 in the next twelve months. This suggests a possible upside of 65.1% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres and Head of Bus. Devel. & Strategy (Age 51, Pay $761.55k)
  • Dr. Claus Juan Møller San Pedro M.D., Ph.D., CEO & Director (Age 59, Pay $960.13k)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 49, Pay $605.53k)
  • Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 42, Pay $545.74k)
  • Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 47)
  • Dr. Torben Lund-Hansen, Sr. VP & Chief Technical Officer (Age 70)
  • Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 57)

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (3.10%), Rice Hall James & Associates LLC (0.22%) and Hillsdale Investment Management Inc. (0.06%). Company insiders that own Y-mAbs Therapeutics stock include Biotech Aps Wg, Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics
.

Which institutional investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, and Thomas Gad.
View insider buying and selling activity for Y-mAbs Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and Hillsdale Investment Management Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $33.40.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics has a market capitalization of $1.46 billion and generates $20.75 million in revenue each year. The company earns $-119,340,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 125 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Where are Y-mAbs Therapeutics' headquarters?

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.